Guggenheim Raises AstraZeneca Price Target Ahead of Q1 Earnings

2 hours ago 3

Joel South

Mon, March 30, 2026 astatine 8:58 AM CDT 4 min read

AstraZeneca (AZN) reported FY2025 gross of $58.74B, up 8% astatine changeless speech rates, with oncology conception gross climbing 17% CER to $25.618B, driven by blockbuster drugs Tagrisso astatine $7.254B and Enhertu astatine $2.775B (up 40% CER), portion Guggenheim raised its terms people to 16,500 GBp with expectations for 20+ Phase 3 proceedings readouts successful 2026.
AstraZeneca’s beardown execution connected oncology maturation and dense pipeline of Phase 3 candidates, combined with a dividend summation to $3.30 per stock and $15B China concern done 2030, positions the institution to prolong mid-to-high single-digit gross maturation and debased double-digit halfway EPS maturation successful 2026.
A caller survey identified 1 azygous wont that doubled Americans’ status savings and moved status from dream, to reality. Read much here.

AstraZeneca PLC (NASDAQ:AZN) has delivered a coagulated trailing 12 months, with shares up 31.43% implicit the past year. Year-to-date, the banal has gained 6.02%, though it has pulled backmost astir 5% implicit the past period from a 52-week precocious of $212.71.

Most Wall Street analysts transportation a statement terms people of $208.54 connected the U.S.-listed ADR. Guggenheim expert Seamus Fernandez, however, conscionable raised his firm's terms people connected AstraZeneca to 16,500 GBp from 16,000 GBp, maintaining a Buy standing aft updating the firm's exemplary up of Q1 earnings. Here is what it would instrumentality for AZN to scope 16,500 GBp by the extremity of 2026.

Read: Data Shows One Habit Doubles American’s Savings And Boosts Retirement

Most Americans drastically underestimate however overmuch they request to discontinue and overestimate however prepared they are. But information shows that people with 1 habit person much than treble the savings of those who don’t.

Fernandez's upgrade follows a exemplary refresh timed to AstraZeneca's Q1 2026 net report, expected May 1. The revision reflects assurance successful the company's execution aft FY2025 full gross of $58.74 billion, up 8% astatine changeless speech rates, and management's guidance for mid-to-high single-digit gross maturation and debased double-digit halfway EPS maturation successful 2026. With 8 buy-equivalent ratings and lone 1 beardown merchantability among tracked analysts, Guggenheim's telephone sits astatine the optimistic extremity of an already constructive Street consensus.

Oncology momentum: The oncology conception generated $25.618 cardinal successful FY2025 revenue, up 17% CER, anchored by Tagrisso astatine $7.254 cardinal and Enhertu astatine $2.775 billion, up 40% CER. This diversified blockbuster portfolio has delivered accordant gross maturation crossed aggregate years.
Pipeline depth: AstraZeneca recorded 16 affirmative Phase 3 readouts and 43 regulatory approvals successful 2025, with 20+ Phase 3 proceedings readouts expected successful 2026 and obesity campaigner elecoglipron advancing to Phase III. Each support represents a imaginable caller gross watercourse for the company.
Capital returns and reinvestment: The institution raised its dividend to $3.30 per stock for 2026 portion committing to a astir one-third summation successful superior expenditures, alongside a $15 cardinal China concern done 2030. This operation of income and reinvestment signals absorption assurance successful semipermanent growth.